Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Phase IIb, Proof of Concept Clinical Study.
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Roflumilast (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms FORTUNA
- 07 Jun 2017 Biomarkers information updated
- 20 Jun 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results published in the Journal of Clinical Endocrinology and Metabolism.
- 20 Jun 2012 Results published in the Journal of Clinical Endocrinology and Metabolism.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History